Author:
Wu Pei-Fen,Yen Shao-Wei,Fan Kuang-Yi,Wang Wen-Fu,Wu Feng-Chu
Publisher
Springer Nature Switzerland
Reference21 articles.
1. BBC: US approves first new Alzheimer's drug in 20 years (2021). https://www.bbc.com/news/health-57383763
2. Biogen (2019): Biogen Plans Regulatory Filing for Aducanumab in Alz-heimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies (2019). http://investors.biogen.com/news-releases/news-re-lease-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease
3. Chapoulie, E., Guerchouche, R., Petit, P. D., Chaurasia, G., Robert, P., Drettakis, G.: Reminiscence therapy using image-based rendering in VR. In 2014 IEEE Virtual Reality (VR), pp. 45–50. IEEE (2014)
4. Kim, O., Pang, Y., Kim, J.H., et al.: The effectiveness of virtual reality for people with mild cognitive impairment or dementia: a meta-analysis. BMC Psychiatry 19(1), 219 (2019)
5. García-Betances, R.I., Arredondo Waldmeyer, M.T., Fico, G., Cabrera-Umpiérrez, M.F.: A succinct overview of virtual reality technology use in Alzheimer’s disease. Frontiers in aging neuroscience 7, 80 (2015)